174 related articles for article (PubMed ID: 25730904)
1. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.
Huang MJ; Hu RH; Chou CH; Hsu CL; Liu YW; Huang J; Hung JS; Lai IR; Juan HF; Yu SL; Wu YM; Huang MC
Oncotarget; 2015 Mar; 6(8):5650-65. PubMed ID: 25730904
[TBL] [Abstract][Full Text] [Related]
2. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
[TBL] [Abstract][Full Text] [Related]
3. RUNX3-Regulated GALNT6 Promotes the Migration and Invasion of Hepatocellular Carcinoma Cells by Mediating O-Glycosylation of MUC1.
Gao F; Zheng G
Dis Markers; 2022; 2022():2959846. PubMed ID: 35909886
[TBL] [Abstract][Full Text] [Related]
4. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
5. CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma cells via activation of the hedgehog signaling pathway.
Liu CH; Lan CT; Chou JF; Tseng TJ; Liao WC
Cancer Lett; 2017 Sep; 403():280-288. PubMed ID: 28652022
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
8. SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma.
Tsao CM; Yan MD; Shih YL; Yu PN; Kuo CC; Lin WC; Li HJ; Lin YW
Hepatology; 2012 Dec; 56(6):2277-87. PubMed ID: 22767186
[TBL] [Abstract][Full Text] [Related]
9. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.
Wu YM; Liu CH; Huang MJ; Lai HS; Lee PH; Hu RH; Huang MC
Cancer Res; 2013 Sep; 73(17):5580-90. PubMed ID: 23832667
[TBL] [Abstract][Full Text] [Related]
10. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway.
Leng C; Zhang ZG; Chen WX; Luo HP; Song J; Dong W; Zhu XR; Chen XP; Liang HF; Zhang BX
Cancer Lett; 2016 Jun; 376(1):188-96. PubMed ID: 26996299
[TBL] [Abstract][Full Text] [Related]
11. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
Peng YY; He YH; Chen C; Xu T; Li L; Ni MM; Meng XM; Huang C; Li J
Cancer Lett; 2016 Jun; 376(1):10-21. PubMed ID: 26975630
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells.
Caja L; Sancho P; Bertran E; Fabregat I
J Hepatol; 2011 Aug; 55(2):351-8. PubMed ID: 21147185
[TBL] [Abstract][Full Text] [Related]
13. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686.
Wu BH; Chen H; Cai CM; Fang JZ; Wu CC; Huang LY; Wang L; Han ZG
Oncotarget; 2016 Feb; 7(6):6847-63. PubMed ID: 26760772
[TBL] [Abstract][Full Text] [Related]
15. Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2.
Zhu B; Sun L; Luo W; Li M; Coy DH; Yu L; Yu W
Oncotarget; 2017 Apr; 8(14):23289-23302. PubMed ID: 28423575
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
[TBL] [Abstract][Full Text] [Related]
17. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
18. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma.
Chen W; Qiu Y
Cell Biochem Biophys; 2015 Jun; 72(2):325-31. PubMed ID: 25561284
[TBL] [Abstract][Full Text] [Related]
20. Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications.
Liao YJ; Fang CC; Yen CH; Hsu SM; Wang CK; Huang SF; Liang YC; Lin YY; Chu YT; Arthur Chen YM
Int J Cancer; 2015 Sep; 137(6):1341-51. PubMed ID: 25754535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
